Conclusion
With the increase in pediatric transplants and more evidence revealing
EBV SMT are not as benign in the pediatric population as previously
thought, further investigations to understand the immune system with
focus on the pediatric transplant population is
warranted15. At
present, the treatment for EBV SMT in the pediatric population remains
individualized with varying reported
successes1,3.
With the limited number of current cases, a multi-center approach
assessing current therapeutic approaches and their efficacies is needed
to create a more standardized approach to the treatment of EBV SMT.